单次大剂量口服后血液中复方新诺明的浓度。
Concentrations of trimethoprim-sulfamethoxazole in blood after a single, large oral dose.
作者信息
Yoshikawa T T, Guze L B
出版信息
Antimicrob Agents Chemother. 1976 Sep;10(3):462-3. doi: 10.1128/AAC.10.3.462.
Abstract
Concentrations of trimethoprim (TMP) and sulfamethoxazole (SMZ) in blood were determined in seven healthy volunteers after ingestion of 720 mg of TMP and 3,600 mg of SMZ (nine tablets of TMP-SMZ, 1:5 ratio) as a single oral dose. The mean levels of drug in blood achieved during the first 8 h after drug administration ranged from 6.12 to 8.32 mug/ml for TMP and 98 to 120 mug/ml for SMZ. These concentrations easily exceeded the previously reported minimal inhibitory concentrations for clinical isolates of Neisseria gonorrhoeae. The combination of TMP-SMZ given as a single, large oral dose may be a useful therapeutic regimen for patients with uncomplicated gonorrhea and susceptible microorganisms.
摘要
在七名健康志愿者单次口服720毫克甲氧苄啶（TMP）和3600毫克磺胺甲恶唑（SMZ）（九片TMP - SMZ，比例为1:5）后，测定了他们血液中的TMP和SMZ浓度。给药后最初8小时内血液中药物的平均水平，TMP为6.12至8.32微克/毫升，SMZ为98至120微克/毫升。这些浓度很容易超过先前报道的淋病奈瑟菌临床分离株的最低抑菌浓度。单次大剂量口服给予TMP - SMZ组合可能是治疗无并发症淋病和易感微生物患者的一种有效治疗方案。
相似文献
1
Concentrations of trimethoprim-sulfamethoxazole in blood after a single, large oral dose.单次大剂量口服后血液中复方新诺明的浓度。
Antimicrob Agents Chemother. 1976 Sep;10(3):462-3. doi: 10.1128/AAC.10.3.462.
2
Treatment of gonorrhea with trimethoprim-sulfamethoxazole.用甲氧苄啶-磺胺甲恶唑治疗淋病。
J Infect Dis. 1977 Jun;135(6):939-43. doi: 10.1093/infdis/135.6.939.
3
Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg).单次服用十二片甲氧苄啶（960毫克）-磺胺甲恶唑（4800毫克）的药代动力学及耐受性
Antimicrob Agents Chemother. 1977 Jul;12(1):102-6. doi: 10.1128/AAC.12.1.102.
4
Pharmacokinetics of sulfamethoxazole and trimethoprim association in hens.磺胺甲恶唑与甲氧苄啶联合用药在母鸡体内的药代动力学
Poult Sci. 1985 Dec;64(12):2362-7. doi: 10.3382/ps.0642362.
5
Pharmacokinetics and body fluid and endometrial concentrations of trimethoprim-sulfamethoxazole in mares.甲氧苄啶-磺胺甲恶唑在母马体内的药代动力学、体液及子宫内膜浓度
Am J Vet Res. 1988 Jun;49(6):918-22.
6
Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis.血液透析期间静脉注射甲氧苄啶-磺胺甲恶唑的药代动力学
Am J Nephrol. 1987;7(4):270-4. doi: 10.1159/000167484.
7
Comparative study of ceftriaxone and trimethoprim-sulfamethoxazole for the treatment of chancroid in Thailand.
J Infect Dis. 1985 Nov;152(5):1002-6. doi: 10.1093/infdis/152.5.1002.
8
Trimethoprim-sulfamethoxazole in the treatment of gonorrhea: comparison with standard treatment schedules.
South Med J. 1975 Sep;68(9):1147-52. doi: 10.1097/00007611-197509000-00020.
9
Pharmacology of trimethoprim-sulfamethoxazole in newborn infants.
J Pediatr. 1982 Apr;100(4):647-50. doi: 10.1016/s0022-3476(82)80778-6.
10
Treatment of concomitant Neisseria gonorrhoeae and Chlamydia trachomatis infections in women: comparison of trimethoprim-sulfamethoxazole with ampicillin-probenecid.女性淋病奈瑟菌和沙眼衣原体合并感染的治疗：甲氧苄啶-磺胺甲恶唑与氨苄西林-丙磺舒的比较
Rev Infect Dis. 1982 Mar-Apr;4(2):491-9. doi: 10.1093/clinids/4.2.491.
引用本文的文献
1
Cyclic di-AMP inhibits thymineless death during infection.环二腺苷酸在感染过程中抑制无胸腺嘧啶死亡。
bioRxiv. 2025 May 14:2025.05.14.654034. doi: 10.1101/2025.05.14.654034.
2
Adsorption and Release of Sulfamethizole from Mesoporous Silica Nanoparticles Functionalised with Triethylenetetramine.三乙烯四胺功能化介孔硅纳米粒子对磺胺甲噁唑的吸附与释放。
Int J Mol Sci. 2021 Jul 17;22(14):7665. doi: 10.3390/ijms22147665.
3
A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions.用于预测MATE1、OCT1、OCT2和CYP2C8药物-药物-基因相互作用的甲氧苄啶基于生理的药代动力学模型。
Pharmaceutics. 2020 Nov 10;12(11):1074. doi: 10.3390/pharmaceutics12111074.
4
Sulfamethoxazole-trimethoprim synergism for Neisseria gonorrhoeae.磺胺甲恶唑-甲氧苄啶对淋病奈瑟菌的协同作用。
Antimicrob Agents Chemother. 1980 Feb;17(2):247-50. doi: 10.1128/AAC.17.2.247.
5
Pharmacokinetics and tolerance of a single twelve-tablet dose of trimethoprim (960 mg)-sulfamethoxazole (4,800 mg).单次服用十二片甲氧苄啶（960毫克）-磺胺甲恶唑（4800毫克）的药代动力学及耐受性
Antimicrob Agents Chemother. 1977 Jul;12(1):102-6. doi: 10.1128/AAC.12.1.102.
本文引用的文献
1
Spectrofluorimetric method for the determination of trimethoprim in body fluids.体液中甲氧苄啶测定的荧光分光光度法。
Chemotherapy. 1969;14:Suppl:22-9. doi: 10.1159/000220652.
2
Therapeutic trial of trimethoprim as a potentiator of sulphonamides in gonorrhoea.甲氧苄啶作为淋病中磺胺类药物增效剂的治疗试验。
Br J Vener Dis. 1967 Sep;43(3):161-5. doi: 10.1136/sti.43.3.161.
3
Gonorrhea in women: treatment with sulfamethoxazole and trimethoprim.女性淋病：用磺胺甲恶唑和甲氧苄啶治疗。
J Infect Dis. 1971 Dec;124(6):533-8. doi: 10.1093/infdis/124.6.533.
4
Treatment of gonorrhoea with trimethoprim-sulphamethoxazole in Uganda.在乌干达用甲氧苄啶-磺胺甲恶唑治疗淋病。
Br J Vener Dis. 1970 Jun;46(3):214-6. doi: 10.1136/sti.46.3.214.
5
Sulphamethoxazole combined with 2-4-diamino-pyrimidines in the treatment of gonorrhoea.磺胺甲恶唑联合2-4-二氨基嘧啶治疗淋病。
Br J Vener Dis. 1970 Feb;46(1):34-6. doi: 10.1136/sti.46.1.34.
6
Comparison of trimethoprim-sulphamethoxazole and penicillin in the treatment of gonorrhoea.甲氧苄啶-磺胺甲恶唑与青霉素治疗淋病的比较。
Br J Vener Dis. 1973 Dec;49(6):517-20. doi: 10.1136/sti.49.6.517.
7
Trimethoprim-sulphamethoxazole in gonorrhoea.
Acta Derm Venereol. 1971;51(5):394-6.
8
Comparison of in vitro susceptibility of Neisseria gonorrhoeae to trimethoprim-sulfamethoxazole on three different media.三种不同培养基上淋病奈瑟菌对甲氧苄啶-磺胺甲恶唑的体外药敏比较。
Antimicrob Agents Chemother. 1975 Nov;8(5):515-7. doi: 10.1128/AAC.8.5.515.
Zotero 插件